Msd K.k.

Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Jun Kusunoki

Lihu Yang

Jun Shibata

Mitsuru Ohkubo

Kenji Niiyama

Tomoharu Iino

Takeru Yamakawa

Hideki Jona

Hideaki Imamura

Koji Yamada

Naomoto Harada

Naomi Murai

Yoshiki Ito

Yukina Tokushima

Takaharu Maruyama

Yoshitaka Tamai

Katsuya Ohbuchi

Katsumi Aragane

It is an object to provide a gene-modified non-human animal having inactivated MGAT2 gene and a gene-modified non-human animal cell, which are useful for the search of the function of MGAT2 in vivo. It is another object to provide a method for screening of a compound capable of inhibiting the activity of MGAT2 and a compound capable of inhibiting the activity of MGAT2. It is further another object to provide a method for detecting a disease induced by abnormal lipid metabolism based on the expression level or activity of MGAT2. A method for screening of a compound by using a gene-modified non-human mammal having the artificially inhibited expression of MGAT2 gene and a cell thereof enable to prevent or treat a disease induced by abnormal lipid metabolism. Also a screening of a compound capable of inhibiting or enhancing the function of MGAT2 enables to prevent or treat a disease induced by abnormal lipid metabolism.

Animal having modification in MGAT2 gene

The invention relates to a compound of a formula (I): or a pharmaceutically acceptable salt or ester thereof, useful as a therapeutic agent for various ACC-related disorders. 

Spirochromanone derivatives as acetyl coenzyme A carboxylase (ACC) inhibitors

The invention relates to a compound of a formula (I): or a pharmaceutically acceptable salt or ester thereof, useful as a therapeutic agent for various ACC-related disorders.

Spirochromanone derivatives

Growing community of inventors

Tsukuba, Japan

Jun Kusunoki